A b s t r a c t
A subset of important hematopoietic progenitor cells is characterized by surface expression of the heavily sialylated glycoprotein CD34. 1 Although the CD34+ fraction of bone marrow cells normally constitutes only about 1.5% of total cells, it participates in the vital process of marrow self-renewal. Studies have indicated that as maturation proceeds, the level of CD34 expression decreases to undetectable levels in mature hematolymphoid cells. 2 The physiologic role of CD34 in hematopoiesis remains largely undefined. However, the fact that it is expressed highly in only immature hematopoietic cells might point to a regulatory role in differentiation and maturation. Diagnostically, detection of CD34 has a central role in the immunophenotypic identification of abnormal blast populations in bone marrow, peripheral blood, and tissues by flow cytometric and immunohistochemical analyses. However, not all leukemic blasts express CD34.
Expression of podocalyxin, a molecule closely related to CD34, has been observed in normal hematopoietic bone marrow progenitor cell populations. 3, 4 In addition, podocalyxin is expressed by podocytes 5 and vascular endothelial cells. 6 A recent report also identified podocalyxin expression in human embryonal carcinoma. 7 First cloned in the rabbit, the human podocalyxin homologue (also called podocalyxin-like protein) has an apparent molecular mass of approximately 160 kd and is a transmembrane glycoprotein with a cytoplasmic tail containing consensus phosphorylation sites for protein kinase C and casein kinase II. 8 The extracellular domain is modified heavily by Olinked glycosylation and the addition of highly charged sialic acid residues. 8 Podocalyxin, CD34, and a third molecule, endoglycan, constitute the CD34 family of sialomucins. [9] [10] [11] Although animal models have indicated that podocalyxin is expressed by the very earliest hematopoietic cells to emerge during embryonic development and by immature precursors in adult bone marrow, 3, 4 embryonic hematopoiesis proceeds normally in podocalyxin-deficient mice. 10 It has been speculated that this could be due to a compensatory increase in the expression of CD34. This hypothesis is supported further by the fact that podocalyxin-deficient mice are affected severely by renal malformations and defects in podocytes, 10 one of the few cell types that normally expresses podocalyxin but not CD34. This highlights the function of podocalyxin in the kidney, the organ system where it has been studied most intensively. Podocalyxin is expressed highly on the foot processes of podocytes, where it aids in the maintenance of spacing between adjacent cells. 5 This is thought to occur via electrostatic repulsion due to the intensely negatively charged podocalyxin present on the apical cell surface.
Consistent with this hypothesis, deletion of the gene that encodes podocalyxin (podxl) results in the embryonic failure of formation of these slit diaphragms and the development of anuria. 10 Therefore, at least in terms of glomerular structure, podocalyxin seems to act as an antiadhesin. Conversely, on vascular endothelial cells, podocalyxin functions as a proadhesin and supports naive immune cell migration into lymph nodes via interactions with L-selectin on circulating lymphocytes in a manner similar to CD34. 12 This proadhesive function has been shown to be critically dependent on tissue-specific glycosylation of podocalyxin and CD34. Given these findings, it seems that podocalyxin has site-and tissue-specific functions that vary greatly depending on the site of expression and the type of posttranslational modifications added to the protein core.
Podocalyxin is expressed in a subset of normal human hematopoietic precursors and in at least 1 leukemia cell line (K562). 4 Transcription of podxl is under the control of the Wilms tumor 1 (WT1) tumor suppressor in podocytes, 13, 14 and WT1 has been shown to be expressed by the majority of blast cells in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). 15 It is, therefore, reasonable to speculate that podocalyxin might be expressed in at least a subset of acute leukemias and myeloid sarcomas. 16, 17 We sought to determine the immunohistochemical expression patterns of podocalyxin by blasts in normal bone marrow biopsy specimens and in bone marrow biopsy specimens or clot sections from patients with acute leukemia. Furthermore, we studied its association with WT1 expression. Podocalyxin expression in cases of extramedullary infiltration by leukemic blasts also was evaluated in a series of myeloid sarcomas.
Materials and Methods

Cases
Approval for the study was obtained from the Cleveland Clinic Foundation Institutional Review Board (Cleveland, OH). Cases were diagnosed and classified according to standard criteria of the World Health Organization 18 and the FrenchAmerican-British (FAB) 19 systems. Five normal bone marrow trephine biopsy specimens (formalin-fixed, paraffin-embedded) were selected randomly as control tissue samples and stained as detailed subsequently for podocalyxin expression.
ALL and AML tissue microarrays (TMAs) were constructed from B-5-or formalin-fixed, paraffin-embedded bone marrow trephine biopsy specimens or bone marrow clot tissue blocks (tissue arrayer from Beecher Instruments, Sun Prairie, WI). In addition to the TMAs, formalin-fixed biopsy specimens from additional cases of acute promyelocytic leukemia (FAB-M3) and acute megakaryoblastic leukemia (FAB-M7) were selected randomly for immunohistochemical staining because these classes of leukemia were not represented on the original TMAs. Cytogenetic analyses were performed as part of the diagnostic evaluation. Additional formalin-fixed biopsy specimens from 15 cases of cutaneous myeloid sarcoma also were selected randomly from tissue archives for evaluation for podocalyxin expression.
Immunohistochemical Analysis
Sections for podocalyxin staining were heat-treated with citrate buffer (pH 6.0) for antigen retrieval and then blocked with 3% hydrogen peroxide. The slides then were subjected to immunohistochemical staining with monoclonal mouse antihuman podocalyxin antibodies (clone 3D3; 1:300 dilution of a 3.0 mg/ml stock solution). 8 Staining was detected with the EnVision detection system (DAKO, Copenhagen, Denmark). Endothelial cells of small vessels on the bone marrow biopsy specimens, TMAs, and skin biopsy specimens exhibited positive staining for podocalyxin and, thus, served as internal positive controls on each tissue section. Immunohistochemical staining for podocalyxin worked equally well in B-5-and formalin-fixed trephine biopsy and aspirate clot sections. H&E stains were reviewed for every case.
In the immunostains, blasts were identified by morphologic examination, and only morphologic blasts were evaluated. More differentiated erythroid or granulocytic precursors were uniformly negative and were not considered in the immunostain score. Megakaryocytes in normal bone marrow were negative for podocalyxin. However, atypical megakaryocytes in 1 case of acute megakaryoblastic leukemia (FAB-M7) were positive for podocalyxin. Podocalyxin staining frequency was evaluated in duplicate by 2 observers (E.D.H. and T.W.K.) in a semiquantitative manner. Positive staining was defined as staining in 5% or more of the blasts. Staining frequency in positively staining blasts was scored as follows: 0, 0% to 4%; 1, 5% to 25%; 2, 26% to 50%; 3, 51% to 75%; and 4, 76% or more. In all cases of positive podocalyxin staining, there was a punctate, dot-like to diffuse cytoplasmic pattern, similar to that seen for CD34.
WT1 and CD34 immunostaining were performed using a modified avidin-biotin complex technique with rabbit polyclonal anti-WT1 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) or monoclonal anti-CD34 antibodies (clone QBEnd/10, Ventana, Tucson, AZ) and a Ventana Benchmark automated immunostaining system. CD34 and WT1 stains were scored in a semiquantitative manner by 2 observers (E.D.H. and T.W.K.) using the same scoring system as outlined for podocalyxin. For WT1, only blasts with a nuclear staining pattern were counted as positive. For statistical purposes, a case was considered positive for any of the aforementioned markers if the staining score was 1 or greater.
Statistical Analysis
Statistical analysis was performed using SPSS software (SPSS, Chicago, IL). For correlational analysis, Spearman r testing (2 -tailed) was used. observed as follows: FAB-M1, 5 (100%) of 5 cases; FAB-M2, 12 (67%) of 18 cases; FAB-M3, 4 (100%) of 4 cases ❚Image 3❚; FAB-M4, 3 (50%) of 6 cases; FAB-M5, 2 (100%) of 2 cases; FAB-M6, 1 (100%) of 1 case; and FAB-M7, 3 (100%) of 3 cases. In 1 FAB-M7 case, atypical megakaryocytes were positive for podocalyxin.
Results
Podocalyxin expression was detected in blasts by
The ALL series was composed of 3 cases of precursor Tcell and 24 cases of precursor B-cell ALL. Podocalyxin expression was detected in leukemic blasts by immunohistochemical analysis in 22 (81%) of 27 cases ❚Table 2❚ and ❚Image 4❚, with strong expression (score of 3 or 4) detected in 6 cases (22%). Interestingly, the percentage of ALL cases expressing podocalyxin was very similar to the percentage of AML cases that were positive (81% and 77%, respectively). of 3 or 4) in 16 cases (41%). CD34 expression was detected by immunohistochemical analysis in 21 (54%) of 39 cases of AML, and, of the 21 CD34+ cases, 16 (76%) also were positive for podocalyxin ❚Image 2❚. Of the AML cases, 5 were CD34+ and negative for podocalyxin, and 14 were CD34-and positive for podocalyxin; 4 cases were negative for both markers by immunohistochemical analysis. There was not a significant correlation between podocalyxin expression and CD34 expression (P = .53) in the AML series. Cytogenetic analysis was available for 35 of 39 cases of AML. Podocalyxin staining was detected in cases with t(8;21)(q22;q22), inv(16)(p13q22), and t(15;17)(q22;q21).
In Table 1 , the AML cases are grouped according to the assigned FAB classification. Podocalyxin expression was ❚Image 2❚ Podocalyxin (brown) and CD34 (red) double immunostain in a case of acute megakaryoblastic leukemia (French-American-British class M7). Double-positive blasts are highlighted by arrows (original magnification ×1,000). Negatively staining erythroid precursors are interspersed.
CD34 expression was detected by immunohistochemical analysis in 18 (67%) of 27 cases of ALL, and 14 (78%) of the CD34+ cases also expressed podocalyxin. Four ALL cases were CD34+ and negative for podocalyxin, and 8 cases were CD34-and positive for podocalyxin. One ALL case was negative for both markers. There was not a significant correlation between podocalyxin expression and CD34 expression (P = .38) in the ALL series. When considering podocalyxin as a lineage-neutral blast marker, it is important to note that detection of this antigen increases the ability to immunophenotypically identify leukemic blasts compared with CD34 alone. Cytogenetic analysis was available for 10 cases of ALL. Four cases contained a t(9;22)(q34;q11.2) translocation, and all were positive for podocalyxin.
Aside from endothelial cells, which were intensely positive in all cases, podocalyxin expression was essentially absent in hematopoietic cells in the 5 normal bone marrow trephine biopsy specimens that were evaluated. This observation is consistent with previous reports wherein podocalyxin expression was identified in only a subset of normal CD34+ marrow cells, 4 a population likely small enough to be undetectable by immunohistochemical analysis.
Because the antiadhesin properties of podocalyxin theoretically could facilitate tissue infiltration, we studied its expression in 15 cases of myeloid sarcoma ❚Table 3❚. The age range for the patients was 25 to 77 (mean, 60.8 years). Podocalyxin was expressed by blasts in 13 (87%) of 15 cases, with strong expression (score of 3 or 4) detected in 8 cases (53%).
Given the role of WT1 in the regulation of podocalyxin in the kidney, 13 we also examined our cases for nuclear expression of this transcription factor. WT1 expression was detected by immunohistochemical analysis in 17 (44%) of 39 cases of AML (Table 1 ) and 21 (78%) of 27 cases of ALL ( Table 2) . The presence of WT1 staining detected by immunohistochemical analysis did not correlate with podocalyxin staining in the AML series (P = .09) or in the ALL series (P = .97). WT1 staining was not performed on the myeloid sarcomas.
Discussion
Podocalyxin is a member of the CD34 family of sialomucins that is expressed normally by early human hematopoietic progenitors. 4 It is a highly negatively charged, cell-surface molecule that might increase the ability of cells to infiltrate tissues 20 or, in the case of podocytes, maintain open slits between adjacent foot processes. Unlike CD34, podocalyxin has not been studied in acute leukemia, although the two are very closely related structurally. Podocalyxin seems to be under transcriptional control of the WT1 tumor suppressor, 13 which also is known to be expressed in blasts. 15 Therefore, we studied the expression of podocalyxin in lymphoid and myeloid leukemic blasts and correlated these data with the expression of CD34 and WT1.
Podocalyxin was expressed by blasts in the majority of cases of AML and ALL and in most cases of cutaneous myeloid sarcoma. A higher percentage of ALL cases expressed podocalyxin compared with AML cases, although the difference was small. Similarly, a higher percentage of the blasts in the myeloid sarcoma cases expressed podocalyxin compared with the AML blasts in bone marrow. Within the AML cases, podocalyxin was expressed in all FAB subtypes tested (M1-M7). Although the numbers of cases in each category were small, M2 and M4 types had the lowest rate of positivity. However, even in these types, at least 50% of the cases expressed podocalyxin. Interestingly, and unlike CD34, podocalyxin seems to be expressed frequently in acute promyelocytic leukemia.
In agreement with previous studies, 15 we also found that WT1 was expressed in a subset of AML and ALL cases. Podocalyxin expression patterns did not seem to correlate with WT1 expression, suggesting that podocalyxin might be dysregulated in acute leukemia. It also is possible that, given its expression in normal hematopoietic progenitors, 4 podocalyxin expression in leukemic blasts is recapitulating the normal expression program, which may not depend on WT1. Although these data suggest that podocalyxin expression patterns are not related to WT1 expression in leukemic blasts, WT1 frequently is mutated in malignant neoplasms, and it is possible that we simply are detecting mutant WT1 in these cases. In such a scenario, mutant forms of WT1 would be unable to act as a transcription factor for podxl and could, in fact, act in a dominant-negative manner. This would account for the lack of correlation between podocalyxin and WT1 expression. We believe this to be unlikely because mutations in the WT1 gene seem to be present in a relatively small percentage of cases of AML (<15%) and an even smaller percentage of cases of ALL. [21] [22] [23] Although the majority of the CD34+ cases also expressed podocalyxin, there were cases of AML and ALL that exhibited expression of only one of these markers. Furthermore, there was no correlation between CD34 and podocalyxin expression. Our data are consistent with a previous analysis of podocalyxin expression in normal human bone marrow cells that showed it was detectable in 28% of CD34+ cells but not in mature leukocytes. 4 Thus, the markers do not seem to be expressed coordinately in normal progenitor cells or in leukemic blasts.
Cytogenetic analysis was available for many cases evaluated. However, the numbers of cases with any particular recurring abnormality were too small to make any firm conclusions. However, it is notable that podocalyxin was seen in AML with t(8;21)(q22;q22), inv(16)(p13q22), and t(15;17)(q22;q21). Within the ALL series, cases with t(9;22)(q34;q11.2) also expressed podocalyxin. Thus, it seems there is no clear predilection for podocalyxin expression in any particular cytogenetic subtype of acute leukemia. As noted, podocalyxin was expressed in cases of AML with t(15;17)(q22;q21), unlike CD34.
We demonstrated that myeloid and lymphoid blast populations in acute leukemia (including myeloid blasts in extramedullary sites) commonly express podocalyxin. WT1 expression does not seem to correlate with podocalyxin expression. From a diagnostic standpoint, expression of podocalyxin in the absence of CD34 suggests that podocalyxin might be another progenitor cell marker that is useful in the immunophenotypic identification of leukemic blasts, including atypical promyelocytic blasts of acute promyelocytic leukemia. The physiologic role of podocalyxin in leukemia remains to be elucidated. 
